BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38359378)

  • 1. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
    Neppelenbroek SIM; Geurts YM; Aleman BMP; Lugtenburg PJ; Rademakers SE; de Weijer RJ; Schippers MGA; Ta BDP; Plattel WJ; Zijlstra JM; van der Maazen RWM; Nijziel MR; Ong F; Schimmel EC; Posthuma EFM; Kersten MJ; Böhmer LH; Muller K; Koene HR; Te Boome LCJ; Bilgin YM; de Jongh E; Janus CPM; van Leeuwen FE; Schaapveld M
    J Clin Oncol; 2024 Jun; 42(16):1903-1913. PubMed ID: 38359378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of male breast cancer after Hodgkin lymphoma.
    de Vries S; Krul IM; Schaapveld M; Janus CPM; Rademakers SE; Roesink JM; Nijziel MR; Bilgin YM; Aleman BMP; van Leeuwen FE
    Blood; 2023 Aug; 142(9):806-811. PubMed ID: 37390297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.
    De Bruin ML; Sparidans J; van't Veer MB; Noordijk EM; Louwman MW; Zijlstra JM; van den Berg H; Russell NS; Broeks A; Baaijens MH; Aleman BM; van Leeuwen FE
    J Clin Oncol; 2009 Sep; 27(26):4239-46. PubMed ID: 19667275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.
    Travis LB; Hill D; Dores GM; Gospodarowicz M; van Leeuwen FE; Holowaty E; Glimelius B; Andersson M; Pukkala E; Lynch CF; Pee D; Smith SA; Van't Veer MB; Joensuu T; Storm H; Stovall M; Boice JD; Gilbert E; Gail MH
    J Natl Cancer Inst; 2005 Oct; 97(19):1428-37. PubMed ID: 16204692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure.
    Krul IM; Opstal-van Winden AWJ; Aleman BMP; Janus CPM; van Eggermond AM; De Bruin ML; Hauptmann M; Krol ADG; Schaapveld M; Broeks A; Kooijman KR; Fase S; Lybeert ML; Zijlstra JM; van der Maazen RWM; Kesminiene A; Diallo I; de Vathaire F; Russell NS; van Leeuwen FE
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):843-853. PubMed ID: 28888722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    Teepen JC; van Leeuwen FE; Tissing WJ; van Dulmen-den Broeder E; van den Heuvel-Eibrink MM; van der Pal HJ; Loonen JJ; Bresters D; Versluys B; Neggers SJCMM; Jaspers MWM; Hauptmann M; van der Heiden-van der Loo M; Visser O; Kremer LCM; Ronckers CM;
    J Clin Oncol; 2017 Jul; 35(20):2288-2298. PubMed ID: 28530852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.
    Krul IM; Boekel NB; Kramer I; Janus CPM; Krol ADG; Nijziel MR; Zijlstra JM; van der Maazen RWM; Roesink JM; Jacobse JN; Schaapveld M; Schmidt MK; Opstal-van Winden AWJ; Sonke GS; Russell NS; Aleman BMP; van Leeuwen FE
    Cancer; 2022 Dec; 128(24):4285-4295. PubMed ID: 36281718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.
    Wong SM; Ajjamada L; Weiss AC; Prakash I; Skamene S; Boileau JF; Pollak MN; Basik M
    Cancer; 2022 Apr; 128(7):1365-1372. PubMed ID: 34919263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer in female survivors of Wilms tumor: a report from the national Wilms tumor late effects study.
    Lange JM; Takashima JR; Peterson SM; Kalapurakal JA; Green DM; Breslow NE
    Cancer; 2014 Dec; 120(23):3722-30. PubMed ID: 25348097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.
    van Eggermond AM; Schaapveld M; Janus CP; de Boer JP; Krol AD; Zijlstra JM; van der Maazen RW; Kremer LC; van Leerdam ME; Louwman MW; Visser O; De Bruin ML; Aleman BM; van Leeuwen FE
    Br J Cancer; 2017 Jul; 117(3):306-314. PubMed ID: 28632726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.
    van Nimwegen FA; Schaapveld M; Janus CP; Krol AD; Petersen EJ; Raemaekers JM; Kok WE; Aleman BM; van Leeuwen FE
    JAMA Intern Med; 2015 Jun; 175(6):1007-17. PubMed ID: 25915855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.
    Lo AC; Liu A; Liu Q; Yasui Y; Castellino SM; Kelly KM; Hererra AF; Friedberg JW; Friedman DL; Schwartz CL; Pei Q; Kessel S; Bergeron-Gravel S; Dama H; Roberts K; Constine LS; Hodgson DC
    JAMA Netw Open; 2024 Jan; 7(1):e2351062. PubMed ID: 38241048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma.
    Conway JL; Connors JM; Tyldesley S; Savage KJ; Campbell BA; Zheng YY; Hamm J; Pickles T
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):35-41. PubMed ID: 27979454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.
    Haberer S; Belin L; Le Scodan R; Kirova YM; Savignoni A; Stevens D; Moisson P; Decaudin D; Pierga JY; Reyal F; Campana F; Fourquet A; Bollet MA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e145-52. PubMed ID: 21605948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk, characteristics, and prognosis of breast cancer after Hodgkin's lymphoma.
    Veit-Rubin N; Rapiti E; Usel M; Benhamou S; Vinh-Hung V; Vlastos G; Bouchardy C
    Oncologist; 2012; 17(6):783-91. PubMed ID: 22588325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
    Sud A; Thomsen H; Sundquist K; Houlston RS; Hemminki K
    J Clin Oncol; 2017 May; 35(14):1584-1590. PubMed ID: 28384078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma.
    Horst KC; Hancock SL; Ognibene G; Chen C; Advani RH; Rosenberg SA; Donaldson SS; Hoppe RT
    Ann Oncol; 2014 Apr; 25(4):848-851. PubMed ID: 24608191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkin's lymphoma: influence on long-term adverse effects (SOPHIA).
    Krul IM; Opstal-van Winden AWJ; Zijlstra JM; Appelman Y; Schagen SB; Meijboom LJ; Serné E; Lambalk CB; Lips P; van Dulmen-den Broeder E; Hauptmann M; Daniëls LA; Aleman BMP; van Leeuwen FE
    BMJ Open; 2018 Sep; 8(9):e018120. PubMed ID: 30206072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort.
    Gibson TM; Mostoufi-Moab S; Stratton KL; Leisenring WM; Barnea D; Chow EJ; Donaldson SS; Howell RM; Hudson MM; Mahajan A; Nathan PC; Ness KK; Sklar CA; Tonorezos ES; Weldon CB; Wells EM; Yasui Y; Armstrong GT; Robison LL; Oeffinger KC
    Lancet Oncol; 2018 Dec; 19(12):1590-1601. PubMed ID: 30416076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy.
    Dores GM; Anderson WF; Beane Freeman LE; Fraumeni JF; Curtis RE
    Br J Cancer; 2010 Sep; 103(7):1081-4. PubMed ID: 20842115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.